Trajectories of Kidney Function in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan.

However, as shown in Table 2 , despite the fact that the median decrease in eGFR during that time was higher in the beneficiaries than in non-beneficiaries, the difference did not reach statistical significance.

also in 111,027 other papers